Susquehanna International Group’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.37M | Buy |
177,300
+115,600
| +187% | +$843K | ﹤0.01% | 7117 |
|
|
2025
Q4 | $378K | Sell |
61,700
-135,200
| -69% | -$1.46M | ﹤0.01% | 9422 |
|
|
2025
Q3 | $3.63M | Buy |
196,900
+180,900
| +1,131% | +$2.91M | ﹤0.01% | 4626 |
|
|
2025
Q2 | $208K | Sell |
16,000
-79,800
| -83% | -$944K | ﹤0.01% | 11129 |
|
|
2025
Q1 | $1.01M | Buy |
95,800
+36,800
| +62% | +$584K | ﹤0.01% | 7231 |
|
|
2024
Q4 | $1M | Sell |
59,000
-25,100
| -30% | -$473K | ﹤0.01% | 6932 |
|
|
2024
Q3 | $1.95M | Buy |
84,100
+28,300
| +51% | +$605K | ﹤0.01% | 5320 |
|
|
2024
Q2 | $1.36M | Sell |
55,800
-94,400
| -63% | -$2.86M | ﹤0.01% | 5881 |
|
|
2024
Q1 | $5.07M | Buy |
150,200
+90,500
| +152% | +$3.21M | ﹤0.01% | 3617 |
|
|
2023
Q4 | $1.88M | Sell |
59,700
-5,800
| -9% | -$138K | ﹤0.01% | 5487 |
|
|
2023
Q3 | $1.67M | Sell |
65,500
-36,800
| -36% | -$1.13M | ﹤0.01% | 5497 |
|
|
2023
Q2 | $2.93M | Buy |
102,300
+300
| +0.3% | +$8.17K | ﹤0.01% | 4408 |
|
|
2023
Q1 | $2.44M | Sell |
102,000
-19,400
| -16% | -$348K | ﹤0.01% | 4736 |
|
|
2022
Q4 | $2.06M | Sell |
121,400
-24,800
| -17% | -$432K | ﹤0.01% | 4650 |
|
|
2022
Q3 | $2.17M | Buy |
146,200
+4,900
| +3% | +$82.2K | ﹤0.01% | 4754 |
|
|
2022
Q2 | $2.22M | Sell |
141,300
-122,300
| -46% | -$2.4M | ﹤0.01% | 4687 |
|
|
2022
Q1 | $7.11M | Buy |
263,600
+112,100
| +74% | +$2.86M | ﹤0.01% | 3063 |
|
|
2021
Q4 | $5.61M | Sell |
151,500
-45,300
| -23% | -$1.85M | ﹤0.01% | 3547 |
|
|
2021
Q3 | $9.4M | Buy |
196,800
+77,200
| +65% | +$3.46M | ﹤0.01% | 2960 |
|
|
2021
Q2 | $4.05M | Sell |
119,600
-291,300
| -71% | -$9.86M | ﹤0.01% | 4418 |
|
|
2021
Q1 | $17M | Sell |
410,900
-2,000
| -0.5% | -$119K | ﹤0.01% | 2082 |
|
|
2020
Q4 | $17.9M | Buy |
412,900
+279,400
| +209% | +$18.9M | ﹤0.01% | 1854 |
|
|
2020
Q3 | $5.73M | Buy |
133,500
+16,500
| +14% | +$819K | ﹤0.01% | 2880 |
|
|
2020
Q2 | $5.47M | Buy |
117,000
+65,500
| +127% | +$2.26M | ﹤0.01% | 2884 |
|
|
2020
Q1 | $700K | Buy |
51,500
+30,300
| +143% | +$388K | ﹤0.01% | 6193 |
|
|
2019
Q4 | $230K | Sell |
21,200
-9,600
| -31% | -$100K | ﹤0.01% | 8509 |
|
|
2019
Q3 | $316K | Sell |
30,800
-9,000
| -23% | -$97.3K | ﹤0.01% | 8188 |
|
|
2019
Q2 | $376K | Buy |
39,800
+28,400
| +249% | +$208K | ﹤0.01% | 7863 |
|
|
2019
Q1 | $78K | Buy |
+11,400
| New | +$58.3K | ﹤0.01% | 8341 |
|
|
2017
Q2 | – | Sell |
-3,414
| Closed | -$27K | – | 9146 |
|
|
2017
Q1 | $27K | Sell |
3,414
-2,315
| -40% | -$21.4K | ﹤0.01% | 8683 |
|
|
2016
Q4 | $84K | Sell |
5,729
-5,200
| -48% | -$77.7K | ﹤0.01% | 9149 |
|
|
2016
Q3 | $189K | Sell |
10,929
-3,800
| -26% | -$123K | ﹤0.01% | 7616 |
|
|
2016
Q2 | $463K | Buy |
14,729
+6,929
| +89% | +$218K | ﹤0.01% | 6258 |
|
|
2016
Q1 | $207K | Buy |
7,800
+3,686
| +90% | +$125K | ﹤0.01% | 7909 |
|
|
2015
Q4 | $181K | Sell |
4,114
-1,172
| -22% | -$52.8K | ﹤0.01% | 8503 |
|
|
2015
Q3 | $223K | Sell |
5,286
-7,400
| -58% | -$389K | ﹤0.01% | 8541 |
|
|
2015
Q2 | $581K | Buy |
12,686
+1,215
| +11% | +$55.7K | ﹤0.01% | 7319 |
|
|
2015
Q1 | $452K | Buy |
11,471
+2,271
| +25% | +$99.9K | ﹤0.01% | 7272 |
|
|
2014
Q4 | $240K | Sell |
9,200
-90,014
| -91% | -$2.86M | ﹤0.01% | 8508 |
|
|
2014
Q3 | $10.7M | Buy |
99,214
+92,857
| +1,461% | +$12.1M | ﹤0.01% | 2040 |
|
|
2014
Q2 | $770K | Buy |
+6,357
| New | +$768K | ﹤0.01% | 6613 |
|
Other funds holding ARCT
AIM
NAMA
VCM
VPM
Susquehanna International Group's ARCT Position: Q1 2026 in Review
Susquehanna International Group increased its Arcturus Therapeutics (ARCT) stake by 173% in Q1 2026, buying an estimated $943K and bringing the position to 204,014 shares worth $1.57M. The position accounts for ﹤0.01% of the portfolio, ranked #6743.
Susquehanna International Group first reported a position in ARCT in Q3 2014 and has held it in 43 quarters since. The position peaked at $9.84M in Q3 2025. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.
- Susquehanna International Group held 204,014 shares of Arcturus Therapeutics worth $1.57M as of Q1 2026.
- Susquehanna International Group bought 129,285 Arcturus Therapeutics shares in Q1 2026, an estimated $943K.
- Arcturus Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6743 holding.
- Susquehanna International Group first reported a position in Arcturus Therapeutics in Q3 2014 and has held it in 43 quarters since.
- Susquehanna International Group's Arcturus Therapeutics position peaked at $9.84M in Q3 2025.
- 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.